Vaccination against measles and rubella for child treated with steroid

Effectiveness of the measles and rubella live attenuated vaccination for pediatric patients treated with not high dose corticosteroid - Effectiveness of the measles and rubella live attenuated vaccination for pediatric patients treated with not high dose corticosteroid

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190014

Enrollment

Registered

2019-04-22

Start date

2019-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases requiring steroid treatments

Interventions

Measles and rubella vaccination for pediatric patients treated with steroid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged from 5 years old to under 15 years old 2. Current treatment with steroids the dose of which satisfies all of the following 2-1.Less than 1mg/kg/day or 2mg/kg/day 2-2.Less than 20mg/day 2-3.No increase in steroids more than 4 weeks or 28 days 3. Patients of inoculation with MR vaccine once at a year old or over

Exclusion criteria

Exclusion criteria: 1. Current treatment with high dose immunosuppressive agents Definition of high dose immunosuppressive agents is as follows Salazosulfapyridine more than 40mg/kg/day Leflunomide more than 0.25mg/kg/day Methotrexate more than 15mg/m2/week Cyclosporine more than 2.5mg/kg/day Tacrolimus more than 0.06mg/kg/day Azathioprine more than 1mg/kg/day Cyclophosphamide more than 0.5mg/kg/day 6-Mercaptopurine more than 1.5mg/kg/day 2. Cases with side effect requiring treatment at the time of MR vaccination in the past 3. Cases with febrile disease within 4 weeks prior to vaccination 4. Cases receiving transfusion or administration of biological products within 3 months prior to vaccination 5. Cases receiving other live attenuated vaccine within 4 weeks or 28 days 6. Cases receiving inactivated vaccine within 6 days 7. Cases diagnosed as primary immunodeficiency disease 8. Cases likely to require treatment enhancement within 4 weeks after vaccination 9. Cases in whom both of measles and rubella antibody titers were higher than criteria 10. Cases living with a pregnant woman

Design outcomes

Primary

Measure	Time frame
Positive sero-conversion rate of specific virus antibody after vaccination	—

Secondary

Measure	Time frame
Comparison of the specific virus antibody titer before and after vaccination	—

Contacts

Public ContactTaku Ishii

Tokyo Medical and Dental University Hospital of Medicine

tishii.ped@tmd.ac.jp+81-3-5803-5249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026